Therapeutic implications of macrolide resistance in pneumococcal community-acquired lower respiratory tract infections

International Journal of Clinical Practice

Volumn 58, Issue 8, 2004, Pages 769-776

  Marrie, Thomas J ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Ketolides; Macrolides; Outcomes; Pneumonia; Resistance

Indexed keywords

AMINOPENICILLIN; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIINFECTIVE AGENT; AZITHROMYCIN; CEFUROXIME AXETIL; CEPHALOSPORIN; CLARITHROMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; KETOLIDE; MACROLIDE; METHYLTRANSFERASE; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TELITHROMYCIN;

ANTIBIOTIC RESISTANCE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TISSUE LEVEL; DRUG TOLERABILITY; DRUG USE; ENZYME ACTIVITY; GENE MUTATION; IN VITRO STUDY; LOWER RESPIRATORY TRACT INFECTION; PRIORITY JOURNAL; REVIEW; RIBOSOME; STREPTOCOCCUS PNEUMONIAE; TREATMENT FAILURE;

COMMUNITY-ACQUIRED INFECTIONS; DRUG RESISTANCE, BACTERIAL; HUMANS; MACROLIDES; PNEUMONIA, PNEUMOCOCCAL; RESPIRATORY TRACT INFECTIONS; TREATMENT OUTCOME;

EID: 4544220313     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1368-5031.2004.00152.x     Document Type: Review

References (88)

1. Torres A, El-Ebiary M, Riquelme R et al. Community-acquired pneumonia in the elderly. Semin Respir Infect 1999; 14: 173-83.
2. Bartlett JG, Dowell SF, Mandell LA et al. Practice guidelines for the management of community-acquired pneumonia in adults. Clin Infect Dis 2000; 31: 347-82.
3. Lieberman D, Lieberman D. Community-acquired pneumonia in the elderly: a practical guide to treatment. Drugs Aging 2000; 17: 93-105.
4. Esposito S, Principi N. Emerging resistance to antibiotics against respiratory bacteria: impact on therapy of community-acquired pneumonia in children. Drug Resist Updat 2002; 5: 73-87.
5. File TM. The epidemiology of respiratory tract infections. Semin Respir Infect 2000; 15: 184-94.
6. Wenzel RP, Edmond MB. Managing antibiotic resistance. N Engl J Med 2000; 343: 1961-3.
7. Gwaltney JM. Pharyngitis. In: Mandell L, Douglas E, Bennett JL, eds. Principles and Practice of Infectious Disease. New York: Churchill Livingstone, 1990, 493-8.
8. LaForce FM. Antibacterial therapy for lower respiratory tract infections in adults: a review. Clin Infect Dis 1992; 14 (Suppl 2): S233-S237.
9. Ball P. Epidemiology and treatment of chronic bronchitis and its exacerbations. Chest 1995; 108 (Suppl 2): 43S-52S.
10. Thornsberry C, Hickey ML, Kahn J et al. Surveillance of antimicrobial resistance among respiratory tract pathogens in the United States, 1997 to 1998. Drugs 1999; 58 (Suppl 2): 361-3.
11. Sethi S. Infectious exacerbations of chronic bronchitis: diagnosis and management. J Antimicrob Chemother 1999; 43 (Suppl A): 97-105.
12. Centers for Disease Control and Prevention. Drug-resistant Streptococcus pneumoniae disease. Factsheet December 2000.
13. Niederman MS, McCombs JS, Unger AN et al. The cost of treating community-acquired pneumonia. Clin Ther 1998; 20: 820-37.
14. Niederman MS, McCombs JS, Unger AN et al. Treatment cost of acute exacerbations of chronic bronchitis. Clin Ther 1999; 21: 576-91.
15. Stein GE, Havlichek DH. Newer oral antimicrobials for resistant respiratory tract pathogens. Which show the most promise? Postgrad Med 1998; 103: 67-76.
16. Bartlett J. Treatment of community-acquired pneumonia. Chemotherapy 2000; 46 (Suppl 1): 24-31.
17. Grossman RF. Guidelines for the treatment of acute exacerbations of chronic bronchitis. Chest 1997; 112 (Suppl 6): 310S-313S.
18. ERS Task Force Report. Guidelines for management of adult community-acquired lower respiratory tract infections. Eur Respir J 1998; 11: 986-91.
19. Heffelfinger JD, Dowell SF, Jorgensen JH et al. Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. Arch Intern Med 2000; 160: 1399-408.
20. Mandell LA, Marrie TJ, Grossman RE et al. Summary of Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Disease Society and the Canadian Thoracic Society. Can Respir J 2000; 7: 371-82.
21. American Thoracic Society. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001; 163: 1730-54.
22. British Thoracic Society. Guidelines for the management of community-acquired pneumonia in adults. Thorax 2001; 56 (Suppl IV): iv1-iv64.
23. Sahm DF, Jones ME, Marsilio M, Thornsberry C. Antimicrobial resistance surveillance in Streptococcus pneumoniae: a comparison of recent surveillance studies. In: Abstracts of the 21st International Congress of Chemotherapy. Birmingham, UK: July, 4-7. 1999. J Antimicrob Chemother 1999; 44 (Suppl 1): 82. [Abstract P192].
24. Thornsberry C, Sahm DF, Kelly LJ et al. Regional trends in antimicrobial resistance among clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States: results from the TRUST surveillance program, 1999-2000. Clin Infect Dis 2002; 34 (Suppl 1): S4-S16.
25. Hyde TB, Gay K, Stephens DS et al. Macrolide resistance among invasive Streptococcus pneumoniae isolates. JAMA 2001; 286: 1857-62.
26. Hoban D, Waites K, Felmingham D. Antimicrobial susceptibility of community-acquired respiratory tract pathogens in North America in 1999-2000: findings of the PROTEKT surveillance study. Diagn Microbiol Infect Dis 2003; 45: 251-9.
27. Felmingham D, Farrell DJ, Reinert RR, Morrissey I. Antibacterial resistance among children with community-acquired respiratory tract infections (PROTEKT 1999-2000). J Infect 2004; 48: 39-55.
28. Zhanel GG, Palatnick L, Nichol KA et al. Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002. Antimicrob Agents Chemother 2003; 47: 1867-74.
29. Felmingham D, Feldman C, Hryniewicz W et al. Surveillance of resistance in bacteria causing community-acquired respiratory tract infections. Clin Microbiol Infect 2002; 8 (Suppl 2): 12-42.
30. Felmingham D, Grüneberg RN, The Alexander Project Group. The Alexander Project 1996-1997: latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections. J Antimicrob Chemother 2000; 45: 191-203.
31. Felmingham D. Evolving resistance patterns in community-acquired respiratory tract pathogens: first results from the PROTEKT global surveillance study. J Infect 2002; 44 (Suppl A): 3-10.
32. Barry AL, Fuchs PC, Brown SD. In vitro activity of the new ketolide HMR 3004 compared to an azalide and macrolides against Streptococcus pneumoniae and Haemophilus influenzae. Eur J Clin Microbiol Infect Dis 1997; 16: 767-9.
33. Farrell DJ, Morrissey I, Bakker S, Felmingham D. Molecular characterization of macrolide resistance mechanisms among Streptococcus pneumoniae and Streptococcus pyogenes isolated from the PROTEKT 1999-2000 study. J Antimicrob Chemother 2002; 50 (Suppl 1): 39-47.
34. Lynch JP III, Martinez FJ. Clinical relevance of macrolide-resistant Streptococcus pneumoniae for community-acquired pneumonia. Clin Infect Dis 2002; 34 (Suppl 1): S27-S46.
35. Farrell DJ, Douthwaite S, Morrissey I et al. Macrolide resistance by ribosomal mutation in clinical isolates of Streptococcus pneumoniae from the PROTEKT 1999-2000 study. Antimicrob Agents Chemoter 2003; 47: 1777-83.
36. Tait-Kamradt A, Davies T, Cronan M et al. Mutations in 23S rRNA and ribosomal protein L4 account for resistance in pneumococcal strains selected in vitro by macrolide passage. Antimicrob Agents Chemother 2000; 44: 2118-25.
37. Cunha B. Antibiotic resistance. Med Clin North Am 2000; 84: 1407-29.
38. Cunha B. Effective antibiotic-resistance control strategies. Lancet 2001; 357: 1307-8.
39. Bell DM. Promoting appropriate antimicrobial drug use: perspective from the Centers for Disease Control and Prevention. Clin Infect Dis 2001; 33 (Suppl 3): S245-S250.
40. Carbon C, Cars O, Christiansen K. Moving from recommendation to implementation and audit: Part 1. Current recommendations and programs: a critical commentary. Clin Microbiol Infect 2002; 8 (Suppl 2): 92-106.
41. Baquero F. Evolving resistance patterns of Streptococcus pneumoniae: a link with long-acting macrolide consumption? J Chemother 1999; 11: 35-43.
42. Cizman M, Pokorn M, Seme K et al. Influence of increased macrolide consumption on macrolide resistance of common respiratory pathogens. Eur J Clin Microbiol Infect Dis 1999; 18: 522-4.
43. Granizo JJ, Aguilar L, Casal J et al. Streptococcus pneumoniae resistance to erythromycin and penicillin in relation to macrolide and β-lactam consumption in Spain (1979-1997). J Antimicrob Chemother 2000; 46: 767-73.
44. Syrogiannopoulos GA, Grivea IN, Davies TA et al. Antimicrobial use and colonization with erythromycin-resistant Streptococcus pneumoniae in Greece during the first 2 years of life. Clin Infect Dis 2000; 31: 887-93.
45. Pihlajamaki M, Kotilainen P, Kaurila T et al. Macrolide-resistant Streptococcus pneumoniae and use of antimicrobial agents. Clin Infect Dis 2001; 33: 483-8.
46. Goossens H, on behalf of the ESAC network. European Study on Antimicrobial Consumption (ESAC): a project funded by DG SANCO of the European Commission. Clin Microbiol Infect 2003; 9 (Suppl 1): 421. [Abstract P1713].
47. Guggenbichler JP, Kastner H. The influence of macrolide antibiotics on the fecal and oral flora. Infect Med 1998; 15: 17-25.
48. Dellamonica P. Preventing the risk of emergence of bacterial resistance associated with antibiotic therapy: what role for pharmacokinetic and pharmacodynamic data? J Antimicrob Chemother 2002; 50: 611-8.
49. Lonks JR, Garau J, Medeiros AA. Implications of antimicrobial resistance in the empirical treatment of community-acquired respiratory tract infections: the case of macrolides. J Antimicrob Chemother 2002; 50 (Suppl C): 87-92.
50. Conte JE Jr, Golden J, Duncan S et al. Single-dose intrapulmonary pharmacokinetics of azithromycin, clarithromycin, ciprofloxacin, and cefuroxime in volunteer subjects. Antimicrob Agents Chemother 1996; 40: 1617-22.
51. Carbon C, Poole MD. The role of the newer macrolides in the treatment of community-acquired respiratory tract infection. A review of experimental and clinical data. J Chemother 1999; 11: 107-18.
52. Zhanel GG, DeCorby M, Noreddin A et al. Pharmacodynamic activity of azithromycin against macrolide-susceptible and -resistant Streptococcus pneumoniae simulating clinically achievable free serum, epithelial lining fluid and middle ear fluid concentrations. J Antimicrob Chemotber 2003; 52: 83-8.
53. Dixon JM. Pneumococcus resistant to erythromycin and lincomycin. Lancet 1967; 1: 573.
54. Medoff G. Pneumonia caused by a pneumococcus resistant to erythromycin and lincomycin. Case report. Mo Med 1974; 71: 496-7.
55. Champion LA, Wald ER, Luddy RE, Schwartz AD. Streptococcus pneumoniae resistant to erythromycin and clindamycin. J Pediatr 1978; 92: 505-6.
56. Sanchez C, Armengol R, Lite J et al. Penicillin-resistant pneumococci and community-acquired pneumonia. Lancet 1992; 339: 988.
57. Lonks JR, Medeiros AA. High rate of erythromycin and clarithromycin resistance among Streptococcus pneumoniae isolates from blood cultures from Providence, R.I. Antimicrob Agents Chemother 1993; 37: 1742-5.
58. Moellering RC. Clinical and public health implications of macrolide-resistant Streptococcus pneumoniae. J Chemother 2002; 14 (Suppl 3): 42-56.
59. Fogarty C, Goldschmidt R, Bush K. Bacteremic pneumonia due to multidrug-resistant pneumococci in 3 patients treated unsuccessfully with azithromycin and successfully with levofloxacin. Clin Infect Dis 2000; 31: 613-5.
60. Garau J, Lonks JR, Gomez L et al. Failure of macrolide therapy in patients with bacteremia due to macrolide resistant Streptococcus pneumoniae. In: Abstracts of the 5th International Conference on the Macrolides, Azalides, Streptogramins, Ketolides. January 26-28, 2000. Seville, Spain: ICMAS, 2000. [Abstract 7.09].
61. Kelley MA, Weber DJ, Gilligan P, Cohen MS. Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin. Clin Infect Dis 2000; 31: 1008-11.
62. Waterer GW, Wunderink RG, Jones CB. Fatal pneumococcal pneumonia attributed to macrolide resistance and azithromycin monotherapy. Chest 2000; 118: 1839-40.
63. Kays MB, Wack MF, Smith DW, Denys GA. Azithromycin treatment failure in community-acquired pneumonia caused by Streptococcus pneumoniae resistant to macrolides by a 23S rRNA mutation. Diagn Microbiol Infect Dis 2002; 43: 163-5.
64. Musher DM, Dowell ME, Shortridge VD et al. Emergence of macrolide resistance during treatment of pneumococcal pneumonia. N Engl J Med 2002; 346: 630-1.
65. Van Kerkhoven D, Peetermans WE, Verbist L, Verhaegen J. Breakthrough pneumococcal bacteraemia in patients treated with clarithromycin or oral β-lactams. J Antimicrob Chemother 2003; 51: 691-6.
66. Pallares R, Linares J, Vadillo M et al. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med 1995; 333: 474-80.
67. Ewig S, Ruiz M, Torres A et al. Pneumonia acquired in the community through drug-resistant Streptococcus pneumoniae. Am J Respir Crit Care Med 1999; 159: 1835-42.
68. Henriques B, Kalin M, Ortqvist A et al. Molecular epidemiology of Streptococcus pneumoniae causing invasive disease in 5 countries. J Infect Dis 2000; 182: 833-9.
69. Lonks JR, Garau J, Gomez L et al. Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae. Clin Infect Dis 2002; 35: 556-64.
70. Heath PT, Breathnach AS. Treatment of infections due to resistant organisms. Br Med Bull 2002; 61: 231-45.
71. Metlay JP. Update on community-acquired pneumonia: impact of antibiotic resistance on clinical outcomes. Curr Opin Infect Dis 2002; 15: 163-7.
72. Moreno S, Garcia-Leoni ME, Cercenado E et al. Infections caused by erythromycin-resistant Streptococcus pneumoniae: incidence, risk factors, and response to therapy in a prospective study. Clin Infect Dis 1995; 20: 1195-200.
73. Singer ME, Harding I, Jacobs MR, Jaffe DH. Impact of antimicrobial resistance on health outcomes in the out-patient treatment of adult community-acquired pneumonia: a probability model. J Antimicrob Chemother 2003; 51: 1269-82.
74. Macfarlane JT, Holmes WE, Macfarlane RM. Reducing reconsultations for acute lower respiratory tract illness with an information leaflet: a randomized controlled study of patients in primary care. Br J Gen Pract 1997; 47: 719-22.
75. Bryskier A, Agouridas C, Chantot JF. Ketolides: new semisynthetic 14-membered ring macrolides. Expanding Indications for the New Macrolides, Azalides and Streptogramins. New York: Marcel Dekker, 1997: 39-50.
76. Schito G, Russo G, Fadda G et al. Telithromycin is highly active against isolates of S. pneumoniae collected from patients with community-acquired respiratory tract infections in Italy (CARTIs; PROTEKT 1999-2001). Clin Microbiol Infect 2002; 8 (Suppl 1): 77.[Abstract P46].
77. Agouridas C, Bonnefoy A, Chantot JF. HMR 3647: antibacterial activity of resistance. In: Abstracts of the 4th International Conference on the Macrolides, Azalides, Streptogramins, Ketolides. January 21-23, 1998. Barcelona, Spain: ICMAS, 1998. [Abstract 1.24].
78. Davies TA, Dewasse BE, Jacobs MR, Appelbaum PC. In vitro development of resistance to telithromycin (HMR 3647), four macrolides, clindamycin, and pristinamycin in Streptococcus pneumoniae. Antimicrob Agents Chemother 2000; 44: 414-7.
79. Khair OA, Andrews JM, Honeybourne D et al. Lung concentrations of telithromycin after oral dosing. J Antimicrob Chemother 2001; 47: 837-40.
80. Muller-Serieys C, Soler P, Cantalloube C et al. Bronchopulmonary disposition of the ketolide antimicrobial, telithromycin (HMR 3647). Antimicrob Agents Chemother 2001; 45: 3104-8.
81. Hagberg L, Rangaraju M, Jenkins S. Efficacy of telithromycin in the treatment of community-acquired pneumonia caused by resistant pneumococci. Clin Microbiol Infect 2002; 8 (Suppl 1): 318. [Abstract P1362].
82. Hagberg L, Carbon C, van Rensburg DJ et al. Telithromycin in the treatment of community-acquired pneumonia: a pooled analysis. Respir Med 2003; 97: 625-33.
83. Pullman J, Boucher P, Lavin B, Patel M. Clinical and bacteriological efficacy of telithromycin vs clarithromycin in patients with community-acquired pneumonia due to Streptococcus pneumoniae, including erythromycin-resistaht strains. In: Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, California, USA, September 27-30, 2002. Washington DC: American Society for Microbiology, 2002: L-372.
84. Aubier M, Aldons PM, Leak A et al. Telithromycin is as effective as amoxicillin/clavulanate in acute exacerbations of chronic bronchitis. Respir Med 2002; 96: 862-71.
85. Fogarty CM, Kohno S, Buchanan P et al. Community-acquired respiratory tract infections caused by resistant pneumococci: clinical and bacteriological efficacy of the ketolide telithromycin. J Antimicrob Chemother 2003; 51: 947-55.
86. van Belkum A, Goessens W, van der Schee C et al. Rapid emergence of ciprofloxacin-resistant enterobacteriaceae containing multiple gentamicin resistance-associated integrons in a Dutch hospital. Emerg Infect Dis 2001; 7: 862-71.
87. Livermore DM, James D, Reacher M et al. Trends in fluoroquinolone (ciprofloxacin) resistance in enterobacteriaceae from bacteremias, England and Wales, 1990-1999. Emerg Infect Dis 2002; 8: 473-8.
88. Christiansen K, Carbon C, Cars O. Moving from recommendation to implementation and audit: Part 2. Review of interventions and audit. Clin Microbiol Infect 2002; 8 (Suppl 2): 107-28.